Medicare & Medicaid
Prices for 25 drugs are expected to decrease for Medicare beneficiaries starting in 2026 and continuing into 2027.
Humana blames higher industry cut points and one contract decreasing to a 3.5-star rating from a 4.5-star rating in 2024.
The report compares cost, care, patient experience and more to brick-and-mortar care, ahead of the expiration of the waiver.
Various forms of a potential separation are reportedly under consideration, though specifics remain unclear.
An audit finds $7.8M in federal funds were claimed for enrollees who were incorrectly assigned to eligibility groups.
The rebates paid by drug companies will be deposited into the Medicare Trust Fund.
The lower MA premiums are expected to drive enrollment to 35.7 million by 2025 - about 51% of all Medicare beneficiaries.
OIG identified systemic issues that impair Medicaid's ability to root out fraudulent activities and offered several recommendations.
Medicare claims for catheters have increased, and CMS found a rise in billings by a small group of durable medical equipment supply companies.
Most states ended the unwinding process with higher total Medicaid and CHIP enrollment than in February 2020.